HA
ABBV icon

Hofer & Associates’s AbbVie ABBV Stock Holding History

Hofer & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$701K Buy
3,225
+65
+2% +$14.4K 0.38% 34
2025
Q4 		$722K Buy
3,160
+25
+0.8% +$5.7K 0.38% 34
2025
Q3 		$726K Buy
+3,135
New +$638K 0.42% 33

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hofer & Associates's ABBV Position: Q1 2026 in Review

Hofer & Associates increased its AbbVie (ABBV) stake by 2.1% in Q1 2026, buying an estimated $14.4K and bringing the position to 3,225 shares worth $701K. The position accounts for 0.38% of the portfolio, ranked #34.

Hofer & Associates first reported a position in ABBV in Q3 2025 and has held it in 3 quarters since. The position peaked at $726K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Hofer & Associates held 3,225 shares of AbbVie worth $701K as of Q1 2026.
  • Hofer & Associates bought 65 AbbVie shares in Q1 2026, an estimated $14.4K.
  • AbbVie made up 0.38% of Hofer & Associates's portfolio in Q1 2026, its #34 holding.
  • Hofer & Associates first reported a position in AbbVie in Q3 2025 and has held it in 3 quarters since.
  • Hofer & Associates's AbbVie position peaked at $726K in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Hofer & Associates's 13F filing for Q1 2026, filed 22 Apr 2026.